Homepage
Healthcare · Biotechnology · United Kingdom · Updated May 10, 8:17pm
$4.25
Price
$712,967
Market Cap
13
Employees
1.16
Beta
Stephen Anthony Stamp
CEO
Business Description
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.07
Stock Price: $4.25
EPS (Diluted): -60.00
EPS (Diluted): -60.00
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.04
Stock Price: $4.25
Total Equity: $11.38M
Shares: 54,861
Total Equity: $11.38M
Shares: 54,861
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.99
Market Cap: $712,967
Total Debt: $60,892
Cash: $8.52M
EBITDA: -$8.08M
Total Debt: $60,892
Cash: $8.52M
EBITDA: -$8.08M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
-$8.0M
Market Cap: $712,967
Total Debt: $60,892
Cash: $8.52M
Total Debt: $60,892
Cash: $8.52M
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$184,857
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$8.27M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$6.24M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-54.8%
Net Income: -$6.24M
Total Equity: $11.38M
Total Equity: $11.38M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
-277.9%
Operating Income: -$8.27M
Tax Rate: 1.6%
Equity: $11.38M
Total Debt: $60,892
Cash: $8.52M
Tax Rate: 1.6%
Equity: $11.38M
Total Debt: $60,892
Cash: $8.52M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.03
Current Assets: $12.42M
Current Liabilities: $6.12M
Current Liabilities: $6.12M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.01
Short-Term Debt: $60,892
Long-Term Debt: $0.00
Total Debt: $60,892
Total Equity: $11.38M
Long-Term Debt: $0.00
Total Debt: $60,892
Total Equity: $11.38M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 54,861
Shares: 54,861
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$207.52
Total Equity: $11.38M
Shares: 54,861
Shares: 54,861
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-98.36
Operating CF: -$5.39M
CapEx: -$1,956
Shares: 54,861
CapEx: -$1,956
Shares: 54,861
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $4.25
Stock Price: $4.25
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$6.24M
Net Income: -$6.24M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares BDRX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $578,000 | $699,000 | $381,000 | $0 | $0 |
| Cost of Revenue | $4.7M | $5.1M | $4.1M | $5.4M | $184,857 |
| Gross Profit | -$4.1M | -$4.4M | -$3.7M | -$5.4M | $-184,857 |
| Operating Expenses | $2.9M | $4.5M | $4.3M | $3.8M | $8.1M |
| Operating Income | -$7.0M | -$8.9M | -$8.0M | -$9.2M | -$8.3M |
| Net Income | -$5.5M | -$7.7M | -$7.1M | -$5.7M | -$6.2M |
| EBITDA | -$5.7M | -$8.3M | -$7.2M | -$9.1M | -$8.1M |
| EPS | $-3,525,000.00 | $-4,943,000.00 | $-229,000.00 | $-1,157,000.00 | $-60.00 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $10.1M | $2.8M | $6.0M | $1.7M | $8.5M |
| Total Current Assets | $11.8M | $4.7M | $7.0M | $8.8M | $12.4M |
| Total Assets | $12.9M | $5.5M | $10.5M | $14.8M | $18.1M |
| Current Liabilities | $1.8M | $1.9M | $5.6M | $5.0M | $6.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.5M | $2.4M | $5.9M | $6.5M | $6.8M |
| Total Equity | $10.5M | $3.2M | $4.7M | $8.3M | $11.4M |
| Retained Earnings | -$127.8M | -$135.3M | -$144.8M | -$150.4M | -$102.6M |
Cash Flow (Annual)
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$6.0M | -$7.0M | -$6.8M | -$12.3M | -$5.4M |
| Capital Expenditure | $-320,000 | $-62,000 | $-263,000 | $-774,000 | $-1,956 |
| Free Cash Flow | -$6.3M | -$7.1M | -$7.1M | -$13.0M | -$5.4M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $17,605 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $2.5M | -$7.2M | $3.1M | -$4.3M | $7.0M |
Analyst Estimates (Annual)
| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$26,378 $26,378 – $26,378
|
$12,296 $12,296 – $12,296
|
$5,687 $5,687 – $5,687
|
$2,843 $2,843 – $2,843
|
| EBITDA |
$-5,275 $-5,275 – $-5,275
|
$-2,459 $-2,459 – $-2,459
|
$-1,137 $-1,137 – $-1,137
|
$-568 $-568 – $-568
|
| Net Income |
$-1,439 $-1,439 – $-1,439
|
$-1,077 $-1,077 – $-1,077
|
$-26 $-26 – $-26
|
$-26 $-26 – $-26
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +20.9% | -45.5% | -100.0% | — |
| Gross Profit Growth | -8.2% | +16.5% | -47.5% | +96.6% |
| Operating Income Growth | -27.6% | +10.3% | -14.8% | +10.1% |
| Net Income Growth | -40.2% | +7.5% | +19.1% | -9.0% |
| EBITDA Growth | -46.0% | +13.3% | -26.8% | +11.0% |
No community reviews yet for BDRX.
Be the first — export the analysis to your AI and contribute back.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27